Formerly Vam Organic Chemicals Ltd, the company underwent name changes, becoming Jubilant Life Sciences Ltd, and ultimately Jubilant Pharmova Ltd in 2021. It stands as a global pharmaceutical giant with three business facets: Pharmaceuticals, Contract Research, and Proprietary Novel Drugs.
Jubilant Pharma Limited, under the Pharmaceuticals umbrella, is bifurcated into the Radiopharmaceuticals Division and the Radiopharmacies Division. This global entity specialises in Nuclear Medicine. Its primary focus is on the development, manufacture, and distribution of top-tier diagnostic and therapeutic agents. Their mission? “IMPROVING LIVES THROUGH NUCLEAR MEDICINE™”. Moreover, their Radiopharmacies Division concentrates on delivering patient-specific radiopharmaceutical services for Nuclear Medicine departments across the U.S. Their clinical applications span diagnostic imaging realms like cardiology, oncology, pulmonary, and others, even offering radiotherapy for thyroid cancer. The Contract Research and Services arm is represented by Jubilant Biosys. Their product range includes Allergy Therapy Products, Sterile Injectables, Active Pharmaceutical Ingredients, and more. Operating out of six USFDA approved manufacturing centres across the U.S., Canada, and India, Jubilant Biosys also facilitates collaborative research for global pharmaceutical pioneers via its research centres in Bengaluru and Noida.
Jubilant Therapeutics Inc. carries the flag for the Proprietary Novel Drugs sector. This innovative entity, devoted to patient wellness, pioneers therapies for oncology and autoimmune disorders. Their allergy therapy products, particularly under the “HollisterStier” brand, have placed them among the U.S.’s top three allergenic extract market players. Remarkably, they’re the exclusive U.S. producer and supplier of venom products for allergy treatments. However, Jubilant Pharmova’s recent financial reports showed an 86% dip in Q1FY24’s net profit, accompanied by decreases in key financial metrics like EBITDA and operating margins. Despite the past year’s critical stance by analysts and fund managers due to these financial shortcomings, the tide seems to be turning. Technical analysts now predict a bullish trajectory for Jubilant Pharmova stocks, projecting a target price of Rs 540 within six months. Additionally, fund managers are showing renewed confidence, adding these stocks to their portfolios, anticipating a robust performance in upcoming quarters.